VivoSim Regains Nasdaq Compliance After $10M Cash Infusion
Event summary
- VivoSim received notice from Nasdaq on August 4, 2026 that it regained compliance with the $2.5M minimum stockholders’ equity requirement.
- The company secured a $5M milestone payment and $1M escrow release from Eli Lilly in July 2026 following the sale of its FXR program.
- VivoSim completed a $4M financing on July 17, 2026, issuing pre-funded warrants at $0.85 per share.
- As of August 3, 2026, VivoSim had approximately $10.1M in cash on hand and 13,390,789 shares outstanding.
The big picture
VivoSim’s financial recovery and Nasdaq compliance come at a critical juncture as the biotech sector increasingly shifts toward human tissue models. The company’s ability to secure $10M in cash within weeks highlights its strategic partnerships, particularly with Eli Lilly, but also raises questions about long-term sustainability given the competitive landscape and regulatory uncertainties.
What we're watching
- Revenue Growth
- Whether VivoSim can sustain its projected 500%+ revenue growth in Fiscal Year 2027 amid increased competition and regulatory shifts.
- Cash Burn Rate
- The pace at which VivoSim depletes its $10.1M cash position, given its operational scale and strategic investments.
- Regulatory Tailwinds
- How the FDA’s push for non-animal testing methods will accelerate adoption of VivoSim’s NAM models among pharmaceutical partners.
Related topics